olopatadine hydrochloride · Alcon Labs Inc · NDA 021545, 206276
Pataday Once Daily Relief
Earliest generic entry, as listed · earliest of 2 marketed strengths
19 May 2032
1 of 2 marketed strengths has no unexpired patent or exclusivity listed.
Blocked by patent: US 8791154, US 9533053.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8791154 | product, use U-1680 | 19 May 2032 |
| US 9533053 | product | 19 May 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 021545-0016 Jan 2026
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021545 · 001 · RLD | solution/drops, ophthalmic | EQ 0.2% BASE | open |
| 206276 · 001 · RLD | solution/drops, ophthalmic | EQ 0.7% BASE | 19 May 2032 |